These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. Thacker SG; Berthier CC; Mattinzoli D; Rastaldi MP; Kretzler M; Kaplan MJ J Immunol; 2010 Oct; 185(7):4457-69. PubMed ID: 20805419 [TBL] [Abstract][Full Text] [Related]
24. B cells and atherosclerosis in systemic lupus erythematosus. Koulouri V; Koutsilieris M; Mavragani CP Expert Rev Clin Immunol; 2019 Apr; 15(4):417-429. PubMed ID: 30652925 [TBL] [Abstract][Full Text] [Related]
25. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. Giannelou M; Mavragani CP J Autoimmun; 2017 Aug; 82():1-12. PubMed ID: 28606749 [TBL] [Abstract][Full Text] [Related]
26. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. Clement M; Charles N; Escoubet B; Guedj K; Chauveheid MP; Caligiuri G; Nicoletti A; Papo T; Sacre K J Autoimmun; 2015 Sep; 63():59-67. PubMed ID: 26183767 [TBL] [Abstract][Full Text] [Related]
28. At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. Grayson PC; Kaplan MJ J Leukoc Biol; 2016 Feb; 99(2):253-64. PubMed ID: 26432901 [TBL] [Abstract][Full Text] [Related]
29. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. McMahon M; Hahn BH Curr Opin Immunol; 2007 Dec; 19(6):633-9. PubMed ID: 18083018 [TBL] [Abstract][Full Text] [Related]
30. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. López-Pedrera C; Barbarroja N; Jimenez-Gomez Y; Collantes-Estevez E; Aguirre MA; Cuadrado MJ Rheumatology (Oxford); 2016 Dec; 55(12):2096-2108. PubMed ID: 27018059 [TBL] [Abstract][Full Text] [Related]
31. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. Kahlenberg JM; Thacker SG; Berthier CC; Cohen CD; Kretzler M; Kaplan MJ J Immunol; 2011 Dec; 187(11):6143-56. PubMed ID: 22058412 [TBL] [Abstract][Full Text] [Related]
32. New insights into the immunopathogenesis of systemic lupus erythematosus. Tsokos GC; Lo MS; Costa Reis P; Sullivan KE Nat Rev Rheumatol; 2016 Nov; 12(12):716-730. PubMed ID: 27872476 [TBL] [Abstract][Full Text] [Related]
33. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. Rahman M; Sing S; Golabkesh Z; Fiskesund R; Gustafsson T; Jogestrand T; Frostegård AG; Hafström I; Liu A; Frostegård J Clin Immunol; 2016 May; 166-167():27-37. PubMed ID: 27102765 [TBL] [Abstract][Full Text] [Related]
34. The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. Bortoluzzi A; Chighizola CB; Fredi M; Raschi E; Bodio C; Privitera D; Gonelli A; Silvagni E; Govoni M; Cavazzana I; Airò P; Meroni PL; Tincani A; Franceschini F; Piantoni S; Casciano F Front Immunol; 2020; 11():572876. PubMed ID: 33193356 [TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Mikołajczyk TP; Osmenda G; Batko B; Wilk G; Krezelok M; Skiba D; Sliwa T; Pryjma JR; Guzik TJ Lupus; 2016 Jan; 25(1):18-27. PubMed ID: 26251402 [TBL] [Abstract][Full Text] [Related]
36. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Zampieri S; Iaccarino L; Ghirardello A; Tarricone E; Arienti S; Sarzi-Puttini P; Gambari P; Doria A Ann N Y Acad Sci; 2005 Jun; 1051():351-61. PubMed ID: 16126977 [TBL] [Abstract][Full Text] [Related]